Literature DB >> 18313498

Chikungunya in Europe.

Benjamin Queyriaux, Alexis Armengaud, Charles Jeannin, Elisabeth Couturier, Françoise Peloux-Petiot.   

Abstract

Mesh：

Year:  2008        PMID： 18313498     DOI： 10.1016/S0140-6736(08)60337-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

2.  Next generation sequencing of DNA-launched Chikungunya vaccine virus.

Authors:  Rachmat Hidajat; Brian Nickols; Naomi Forrester; Irina Tretyakova; Scott Weaver; Peter Pushko
Journal:  Virology       Date:  2016-02-06       Impact factor: 3.616

3.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

4.  Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.

Authors:  Amanda Piper; Mariana Ribeiro; Katherine M Smith; Caitlin M Briggs; Emerson Huitt; Kavita Nanda; Carla J Spears; Michelle Quiles; John Cullen; Malcolm E Thomas; Dennis T Brown; Raquel Hernandez
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

5.  Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Authors:  Pankaj Pal; Julie M Fox; David W Hawman; Yan-Jang S Huang; Ilhem Messaoudi; Craig Kreklywich; Michael Denton; Alfred W Legasse; Patricia P Smith; Syd Johnson; Michael K Axthelm; Dana L Vanlandingham; Daniel N Streblow; Stephen Higgs; Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

6.  Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells.

Authors:  Kristina S Burrack; Jeslin J L Tan; Mary K McCarthy; Zhisheng Her; Jennifer N Berger; Lisa F P Ng; Thomas E Morrison
Journal:  PLoS Pathog       Date:  2015-10-05       Impact factor: 6.823

Review 7.  Potential changes in disease patterns and pharmaceutical use in response to climate change.

Authors:  Clare H Redshaw; Will M Stahl-Timmins; Lora E Fleming; Iain Davidson; Michael H Depledge
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

8.  Kinetic analysis of mouse brain proteome alterations following Chikungunya virus infection before and after appearance of clinical symptoms.

Authors:  Christophe Fraisier; Penelope Koraka; Maya Belghazi; Mahfoud Bakli; Samuel Granjeaud; Matthieu Pophillat; Stephanie M Lim; Albert Osterhaus; Byron Martina; Luc Camoin; Lionel Almeras
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

9.  Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.

Authors:  Zhisheng Her; Terk-Shin Teng; Jeslin J L Tan; Teck-Hui Teo; Yiu-Wing Kam; Fok-Moon Lum; Wendy W L Lee; Christelle Gabriel; Rossella Melchiotti; Anand K Andiappan; Valeria Lulla; Aleksei Lulla; Mar K Win; Angela Chow; Subhra K Biswas; Yee-Sin Leo; Marc Lecuit; Andres Merits; Laurent Rénia; Lisa F P Ng
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

10.  A polarized cell model for Chikungunya virus infection: entry and egress of virus occurs at the apical domain of polarized cells.

Authors:  Pei Jin Lim; Justin Jang Hann Chu
Journal:  PLoS Negl Trop Dis       Date:  2014-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.